StrainX raises US$13 million to scale fermentation platform

StrainX Bioworks secured US$13 million in fresh funding to scale its precision fermentation platform and expand production of high-value food and nutritional ingredients. The Indian startup aims to strengthen its position in the global biomanufacturing market while preparing for commercial expansion in the US and India, according to AgFunderNews.

The investment round was led by Prime Venture Partners and Leo Capital, with participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dholakia Ventures and WindT Angels from IIT Delhi. The company plans to use the capital to increase fermentation capacity and accelerate commercialization of its first products.

As reported by AgFunderNews, StrainX already operates a 10,000-liter fermentation facility in Bhopal and expects to scale progressively toward 100,000 liters by late next year through a modular expansion strategy.

“We already have 10,000-liter fermentation capacity operational, and we have generated repeatable results at that level,” said cofounder Akshay Mittal. He added that the company’s infrastructure was specifically designed to support phased growth while maintaining operational efficiency.

Founded in 2023 by Mittal and Alok Malaviya, PhD, StrainX focuses on precision fermentation, a technology that uses microorganisms to produce ingredients such as proteins, flavors and nutritional compounds. The startup develops its technology internally and manages the full production chain, including scale-up, manufacturing and ingredient formulation.

“We develop our own technology, handle our own scale-up, build our own manufacturing, and take products through development and commercialization ourselves,” Mittal explained. The company believes this vertically integrated approach can generate long-term cost advantages and greater control over innovation.

One of StrainX’s main objectives is to partner with major global food and beverage companies seeking sustainable ingredient solutions. The startup has already begun trials with approximately 20 to 25 companies in India and the United States for its first commercial molecule.

According to the company, one ingredient has already received self-GRAS status in the US, while documentation has also been submitted to the FDA. A second product is expected to reach commercialization within the next 12 to 18 months.

StrainX is also investing heavily in application and formulation expertise, helping customers integrate precision fermentation ingredients into finished products. The company argues that adoption becomes faster when ingredient developers actively support formulation and product development.

Another key element behind the company’s strategy is India’s manufacturing potential. Mittal believes the country can become a global leader in fermentation-based production thanks to lower operating costs, strong engineering talent and access to raw materials.

“I believe that India is going to be the fermentation capital of the world,” he said. According to Mittal, building and operating fermentation infrastructure in India can cost between one-third and one-quarter of similar facilities in Europe or the United States.

The company also highlighted support from the Indian government for biotechnology and biomanufacturing initiatives. Combined with private investment, StrainX expects this environment to accelerate its expansion plans.

Beyond fermentation tanks, the company is developing advanced downstream processing capabilities that include centrifugation, filtration systems, ion exchange chromatography and spray drying. These technologies are critical for producing food-grade ingredients at industrial scale.

The broader precision fermentation sector has gained momentum globally as food companies search for more sustainable and scalable ingredient production methods. StrainX is positioning itself as one of the emerging players seeking to build a globally relevant food biotech business from India.